GMP Annexes: Complete Guide to EU GMP Annexes
Understand the EU GMP Annexes, their purpose and application in pharmaceutical manufacturing, including sterile products, biologicals, computerized systems, qualification and validation, Qualified Person certification, real-time release testing, reference samples and medicinal-product importation.
GMP Annexes are specialized parts of the European Union Good Manufacturing Practice framework that provide additional requirements and guidance for particular products, technologies, manufacturing activities and quality-system operations.
While the main chapters of EU GMP describe the fundamental requirements of pharmaceutical manufacturing, the annexes address situations where additional or more specific controls are necessary. Examples include sterile manufacturing, computerized systems, qualification and validation, biological products and imported medicinal products.
If you are new to pharmaceutical GMP, begin with our cGMP Basics of Pharmaceuticals and GMP Principles of Pharmaceuticals before studying the individual annexes.
What are GMP Annexes?
GMP Annexes provide additional guidance for manufacturing situations that require controls beyond the general requirements described in the main GMP chapters.
For example, production of a conventional non-sterile tablet and manufacture of a sterile injectable product do not present identical risks. Sterile manufacture therefore requires additional controls for contamination prevention, cleanrooms, environmental monitoring, aseptic processing and sterilization.
In the same way, computerized systems, radiopharmaceuticals, biological medicines, medicinal gases and imported medicines each require specific controls that are addressed through relevant annexes.
How GMP Annexes Fit into EudraLex Volume 4
EU pharmaceutical GMP guidance is organized within EudraLex Volume 4. Understanding this structure makes it easier to determine where a specific requirement originates.
Companies therefore need to apply the relevant main GMP requirements together with any annexes that apply to their product, process or operation.
Complete List of EU GMP Annexes
The following annexes are currently listed by the European Commission for medicinal products for human use. The numbering is not continuous, so gaps between annex numbers are normal.
Manufacture of Sterile Medicinal Products
Covers contamination control, cleanroom classification, environmental monitoring, aseptic processing, sterilization, barrier technologies, personnel practices and other controls required for sterile pharmaceutical manufacture.
Manufacture of Biological Active Substances and Medicinal Products for Human Use
Addresses manufacturing considerations associated with biological materials and products, including variability of biological systems, contamination risks and appropriate process controls.
Manufacture of Radiopharmaceuticals
Provides GMP considerations for radiopharmaceutical manufacture, where pharmaceutical quality requirements must be combined with appropriate radiation-safety controls.
Manufacture of Medicinal Gases
Addresses production, filling, storage, equipment, containers, traceability and quality controls for medicinal gases.
Manufacture of Herbal Medicinal Products
Covers GMP considerations associated with herbal starting materials and medicinal products, including identity, variability, processing, storage and contamination control.
Sampling of Starting and Packaging Materials
Provides principles for obtaining representative samples of raw materials and packaging components while preventing contamination, mix-ups and sampling errors.
Manufacture of Liquids, Creams and Ointments
Addresses specific risks associated with non-sterile liquids and semi-solid products, including microbial contamination, equipment, transfer systems and manufacturing controls.
Manufacture of Pressurised Metered Dose Aerosol Preparations for Inhalation
Focuses on specialized controls required for pressurized metered-dose inhalation products and their manufacturing and filling processes.
Computerised Systems
Establishes expectations for computerized systems used in GMP operations, including validation, security, access control, electronic records, audit trails, backup, business continuity and data integrity.
Use of Ionising Radiation in the Manufacture of Medicinal Products
Covers controls for the use of ionising radiation during pharmaceutical manufacturing, including process validation, dosimetry and routine process control.
Investigational Medicinal Products
Addresses GMP expectations relevant to investigational medicinal products used in clinical trials, including manufacture, packaging, labeling and release responsibilities.
Manufacture of Products Derived from Human Blood or Human Plasma
Provides specific GMP considerations for plasma-derived and blood-derived medicinal products, including traceability, collection-related controls and biological safety.
Qualification and Validation
Covers lifecycle qualification and validation activities, including facilities, utilities, equipment, processes, cleaning, transport, change control and requalification.
Certification by a Qualified Person and Batch Release
Describes responsibilities relating to Qualified Person certification and batch release, including confirmation that batches comply with relevant requirements before release.
Real Time Release Testing and Parametric Release
Describes conditions under which appropriately controlled manufacturing and analytical strategies may support real-time release testing or parametric release.
Reference and Retention Samples
Defines expectations for reference and retention samples, including their purpose, storage, availability and lifecycle. A revised Annex 19 has been published with an application date of 24 September 2026.
Importation of Medicinal Products
Addresses GMP responsibilities associated with importing medicinal products from outside the European Union or European Economic Area, including documentation, testing, supply-chain oversight and batch-certification considerations.
EU GMP Annexes at a Glance
| Annex | Subject | Main GMP Focus |
|---|---|---|
| 1 | Sterile Medicinal Products | Aseptic processing and contamination control |
| 2 | Biological Products | Biological manufacturing risks |
| 3 | Radiopharmaceuticals | GMP plus radiation-related controls |
| 6 | Medicinal Gases | Gas manufacture, filling and containers |
| 7 | Herbal Medicinal Products | Herbal materials and product controls |
| 8 | Sampling | Starting and packaging material sampling |
| 9 | Liquids, Creams and Ointments | Non-sterile liquid and semi-solid manufacture |
| 10 | Pressurised Metered Dose Aerosols | Specialized inhalation-product manufacture |
| 11 | Computerised Systems | Validation, security and electronic data |
| 12 | Ionising Radiation | Radiation processes and validation |
| 13 | Investigational Medicinal Products | Clinical-trial product manufacture |
| 14 | Blood or Plasma Derived Products | Biological safety and traceability |
| 15 | Qualification and Validation | Lifecycle validation |
| 16 | QP Certification and Batch Release | Batch certification and release |
| 17 | Real Time Release / Parametric Release | Alternative release strategies |
| 19 | Reference and Retention Samples | Sample retention and availability |
| 21 | Importation of Medicinal Products | Imported-product GMP controls |
GMP Annex 1: Manufacture of Sterile Medicinal Products
Why Annex 1 is Especially Important
Sterile pharmaceutical products present a particularly high risk because microbiological contamination or other contamination may directly affect patient safety.
Annex 1 therefore emphasizes an integrated Contamination Control Strategy (CCS) supported by facility design, personnel controls, environmental monitoring, cleaning, disinfection, sterilization, process knowledge and Quality Risk Management.
Important Annex 1 Areas
- Pharmaceutical Quality System
- Premises
- Equipment
- Utilities
- Personnel
- Production and specific technologies
- Environmental and process monitoring
- Quality Control
- Contamination Control Strategy
The revised Annex 1 became fully applicable on 25 August 2024.
GMP Annex 11: Computerised Systems
Annex 11 is especially important for modern pharmaceutical manufacturing because GMP activities increasingly rely on electronic systems.
Examples include LIMS, electronic batch records, chromatography data systems, ERP systems, environmental monitoring software, computerized manufacturing equipment and electronic document management systems.
Major Annex 11 Concepts
- Computerized system validation
- Quality Risk Management
- Supplier and service-provider assessment
- User access management
- Electronic records
- Audit trails
- Data backup
- Security controls
- Incident management
- Business continuity
- Periodic evaluation
Annex 11 should therefore be considered together with broader pharmaceutical data-integrity and computerized-system lifecycle controls.
GMP Annex 15: Qualification and Validation
Annex 15 provides a lifecycle framework for qualification and validation. Pharmaceutical manufacturers should plan validation activities according to product, process and system risks rather than treating validation as a single one-time exercise.
Key Annex 15 Areas
- Validation planning
- Qualification stages
- Process validation
- Verification of transport
- Packaging validation
- Qualification of utilities
- Cleaning validation
- Change control
- Requalification
Qualification stages may include activities commonly described as DQ, IQ, OQ and PQ, where appropriate to the system being qualified.
GMP Annex 16: Qualified Person Certification and Batch Release
Annex 16 addresses the certification of medicinal-product batches by a Qualified Person and the controls that support batch release.
Batch certification is not simply a review of the finished-product test result. It depends on assurance that manufacturing, testing, documentation and relevant supply-chain activities meet applicable requirements.
Important Annex 16 Considerations
- Qualified Person responsibilities
- Batch certification
- Manufacturing authorization
- Supply-chain controls
- Outsourced activities
- Testing arrangements
- Deviations affecting certification
- Documentation supporting release
GMP Annex 21: Importation of Medicinal Products
Annex 21 addresses GMP activities associated with medicinal products imported into the European Union or European Economic Area from third countries.
It reinforces the importance of understanding where manufacture and testing have occurred and ensuring that appropriate documentation, controls and responsibilities support imported-product certification and release.
Important Areas
- Importation-site responsibilities
- Supply-chain knowledge
- Documentation availability
- Testing arrangements
- Traceability
- Quality agreements
- Batch certification
How Should Pharmaceutical Companies Apply GMP Annexes?
A manufacturer should first identify which annexes apply to its products, manufacturing technologies and quality systems.
Example
A company producing sterile injectable products using computerized manufacturing systems may need to consider several requirements together, including:
- EU GMP Part I requirements
- Annex 1 for sterile manufacture
- Annex 11 for computerized systems
- Annex 15 for qualification and validation
- Annex 16 for QP certification and batch release
GMP compliance therefore requires an integrated approach rather than treating each annex as an isolated document.
Who Should Understand GMP Annexes?
Common GMP Annex Compliance Mistakes
GMP Annex Compliance Checklist
Key Takeaway
EU GMP Annexes convert general GMP principles into more specific controls for specialized products, processes and technologies. Pharmaceutical manufacturers should determine which annexes apply to their activities, integrate those requirements into the Pharmaceutical Quality System, train relevant personnel, perform documented gap assessments and continually monitor changes to the regulatory framework. Compliance is strongest when the annexes are applied together with the main GMP requirements, Quality Risk Management and lifecycle quality principles.
Frequently Asked Questions About GMP Annexes
1. What are GMP Annexes?
GMP Annexes are specialized sections of EU GMP that provide additional guidance and requirements for particular pharmaceutical products, systems, processes and manufacturing technologies.
2. How many EU GMP Annexes are currently listed?
The current European Commission list for medicinal products for human use contains 17 annexes: Annexes 1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19 and 21.
3. Why are some GMP Annex numbers missing?
The present EU GMP annex list does not use every consecutive number. The numbering reflects the historical development of the GMP framework, so gaps in the sequence are normal.
4. What is EU GMP Annex 1?
Annex 1 covers the manufacture of sterile medicinal products and includes requirements relating to contamination control, cleanrooms, aseptic processing, sterilization and environmental monitoring.
5. What is EU GMP Annex 11?
Annex 11 addresses computerized systems used in GMP activities, including validation, access control, electronic records, security, audit trails, backup and data integrity.
6. What is EU GMP Annex 15?
Annex 15 covers qualification and validation of pharmaceutical facilities, utilities, equipment, manufacturing processes, cleaning processes and other relevant systems.
7. What is EU GMP Annex 16?
Annex 16 covers certification by a Qualified Person and batch release of medicinal products.
8. What is EU GMP Annex 21?
Annex 21 addresses GMP requirements associated with importing medicinal products from outside the European Union or European Economic Area.
9. Do all GMP Annexes apply to every pharmaceutical company?
No. Applicability depends on the products manufactured, processes used, technologies involved and activities performed by the organization.
10. Should GMP Annexes be used together with Part I?
Yes. Applicable annexes supplement the main GMP requirements and generally need to be considered together with the relevant parts of the overall EU GMP framework.
11. What is the difference between GMP chapters and annexes?
The main GMP chapters establish broad pharmaceutical quality and manufacturing requirements, whereas annexes provide more specific expectations for particular products, processes or technologies.
12. Why should GMP Annexes be reviewed regularly?
GMP guidance changes over time. Regular review helps ensure that procedures, facilities, systems, training and validation remain aligned with applicable requirements.
.webp)
